cd36

Introduction

Pathway Diagram

flowchart TD
    AmyloidBeta["Amyloid beta<br/>Protein"]
    CD36_protein["CD36<br/>Protein"]
    CD36_gene["CD36<br/>Gene"]
    PINK1["PINK1<br/>Mitochondrial Kinase"]
    Pericytes["Pericytes<br/>Blood-Brain Barrier"]
    Neuroinflammation["Neuroinflammation<br/>CNS Inflammation"]
    Alzheimer["Alzheimer's<br/>Disease"]
    ALS["Amyotrophic Lateral<br/>Sclerosis (ALS)"]
    MS["Multiple<br/>Sclerosis (MS)"]
    Stroke["Stroke<br/>Cerebrovascular Disease"]
    Inflammation["Systemic<br/>Inflammation"]
    Atherosclerosis["Atherosclerosis<br/>Vascular Disease"]
    MitochondrialFunction["Mitochondrial<br/>Function"]
    BBBIntegrity["Blood-Brain Barrier<br/>Integrity"]
    NeurodegenerativeOutcome["Neurodegeneration<br/>Progression"]

    AmyloidBeta -->|"activates"| CD36_protein
    CD36_protein -->|"regulates"| Pericytes
    CD36_protein -->|"activates"| PINK1
    PINK1 -->|"promotes"| MitochondrialFunction
    Pericytes -->|"maintains"| BBBIntegrity
    
    CD36_gene -->|"activates"| Neuroinflammation
    CD36_gene -->|"activates"| Inflammation
    CD36_gene -->|"activates"| MS
    CD36_gene -->|"activates"| Stroke
    CD36_gene -->|"associated_with"| Alzheimer
    CD36_gene -->|"associated_with"| Atherosclerosis
    CD36_gene -->|"inhibits"| ALS
    
    Neuroinflammation -->|"promotes"| NeurodegenerativeOutcome
    Inflammation -->|"contributes_to"| NeurodegenerativeOutcome
    BBBIntegrity -->|"protects_against"| NeurodegenerativeOutcome
    MitochondrialFunction -->|"protects_against"| NeurodegenerativeOutcome

    style CD36_protein fill:#006494
    style CD36_gene fill:#006494
    style PINK1 fill:#4a1a6b
    style MitochondrialFunction fill:#1b5e20
    style BBBIntegrity fill:#1b5e20
    style Neuroinflammation fill:#ef5350
    style Inflammation fill:#ef5350
    style NeurodegenerativeOutcome fill:#5d4400
    style Alzheimer fill:#5d4400
    style ALS fill:#5d4400
    style MS fill:#5d4400
    style Stroke fill:#5d4400

CD36 (Cluster of Differentiation 36), also known as Scavenger Receptor Class B Member 1 (SCARB1), is a multifunctional class B scavenger receptor encoded by the CD36 gene located on chromosome 7q21.11^{1CD36 mediates the innate immune responses to neurodegenerative deposits in the brain2003 · Nature · PMID 14532259Open reference}. This transmembrane glycoprotein is expressed on various cell types, including macrophages, microglia, platelets, adipocytes, and endothelial cells, where it participates in diverse physiological and pathological processes including fatty acid transport, oxidized low-density lipoprotein (oxLDL) uptake, immune responses, and phagocytosis of apoptotic cells

In the context of neurodegenerative diseases, CD36 has emerged as a critical receptor mediating the innate immune responses to amyloid-beta (Abeta) deposits in the brain

Gene and Protein Structure

Gene Location and Organization

The CD36 gene spans approximately 32.5 kb on the long arm of chromosome 7 at position 21.11 (7q21.11)^{3Cellular RNA interacts with MAVS to promote antiviral signaling.2024 · Science (New York, N.Y.) · DOI 10.1126/science.adl0429 · PMID 39700280Open reference}. The gene consists of 15 exons encoding a 472-amino acid protein with a molecular weight of approximately 88 kDa. Multiple transcript variants have been described, resulting in alternative splicing that produces proteins with varying functional domains.

Protein Architecture

CD36 is a member of the class B scavenger receptor family, characterized by:

• N-terminal extracellular domain: Contains two transmembrane regions flanking a large extracellular loop (~300 amino acids) that houses the ligand-binding sites

• C-terminal cytoplasmic tail: Short intracellular domains (≤10 amino acids) at both N- and C-termini that mediate signaling through association with Src family kinases

• Ligand-binding pocket: Recognizes diverse ligands including oxLDL, amyloid-beta, fatty acids, and pathogen-associated molecular patterns (PAMPs)

The protein contains multiple post-translational modification sites, including N-linked glycosylation that is essential for proper trafficking and function^{4Genomic loci with pleiotropic effects on coronary artery calcification.2006 · Atherosclerosis · DOI 10.1016/j.atherosclerosis.2005.06.010 · PMID 16054150Open reference}.

Expression Patterns

Tissue Distribution

CD36 exhibits broad tissue distribution with highest expression in:

• ** adipose tissue ** (adipocytes)

• muscle tissue (skeletal and cardiac muscle)

• hematopoietic cells (macrophages, monocytes, platelets)

• liver (Kupffer cells, hepatocytes)

• brain (microglia, astrocytes, neurons)

Brain Expression

In the central nervous system, CD36 is predominantly expressed on microglia, the resident immune cells of the brain

Physiological Functions

Lipid Metabolism

CD36 plays a central role in cellular lipid homeostasis through several mechanisms:

Fatty Acid Uptake: CD36 facilitates the import of long-chain fatty acids into cells, particularly in metabolic tissues like adipose tissue and muscle. This function is crucial for energy metabolism and storage^{5Identification of type 2 diabetes loci in 433,540 East Asian individuals.2020 · Nature · DOI 10.1038/s41586-020-2263-3 · PMID 32499647Open reference}.

Oxidized LDL Clearance: As a scavenger receptor, CD36 mediates the uptake of oxidized LDL by macrophages, contributing to foam cell formation and atherosclerosis development. This pathway is particularly relevant given the links between cardiovascular health and neurodegenerative disease.

Lipid Raft Organization: CD36 localizes to lipid rafts, membrane microdomains enriched in cholesterol and sphingolipids, where it initiates signaling cascades upon ligand binding.

Immune Function

CD36 serves as a pattern recognition receptor (PRR) with broad specificity:

Pathogen Recognition: CD36 recognizes various pathogen-associated molecular patterns, including bacterial lipopolysaccharide (LPS), fungal cell wall components, and viral proteins.

Apoptotic Cell Clearance: The receptor mediates phagocytosis of apoptotic cells, essential for tissue remodeling and resolution of inflammation.

Inflammatory Signaling: CD36 engagement triggers intracellular signaling through Syk, PI3K, and MAPK pathways, leading to production of pro-inflammatory cytokines and reactive oxygen species (ROS)^{6CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability.2022 · Cell metabolism · DOI 10.1016/j.cmet.2021.02.015 · PMID 33691090Open reference}.

Role in Alzheimer’s Disease

Amyloid-beta Recognition and Response

CD36 serves as a major receptor for Aβ on microglia, playing a dual role in disease pathogenesis^{7The complement system and human autoimmune diseases.2023 · Journal of autoimmunity · DOI 10.1016/j.jaut.2022.102979 · PMID 36535812Open reference}:

Pro-inflammatory Signaling: Upon Aβ binding, CD36 recruits the adapter proteins Fyn and Syk, leading to activation of downstream signaling cascades including:

• NF-κB activation and inflammatory cytokine production (IL-1β, TNF-α, IL-6)

• NADPH oxidase activation and ROS generation

• NLRP3 inflammasome assembly and activation

Phagocytic Function: Paradoxically, CD36 also mediates Aβ uptake and clearance by microglia. However, this phagocytic capacity becomes impaired in chronic disease states, contributing to Aβ accumulation^{8Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.2023 · Cell chemical biology · DOI 10.1016/j.chembiol.2023.07.005 · PMID 37557181Open reference}.

Evidence from Animal Models

Multiple lines of evidence from mouse models support CD36’s role in AD:

• CD36 knockout mice display reduced microglial activation and improved cognitive performance in APP/PS1 and 5XFAD models

• CD36 deficiency attenuates early neuroinflammation without affecting amyloid plaque load

• CD36 overexpression in microglia enhances inflammatory responses to Aβ

• Pharmacological inhibition of CD36 reduces pro-inflammatory cytokine production in vivo

Genetic Associations

Population studies have identified CD36 polymorphisms associated with AD risk:

• rs1997689: Associated with altered AD risk in APOE ε4 carriers

• rs3211938: Linked to reduced AD incidence in some populations

• Haplotype analyses suggest complex gene-environment interactions

CD36 in Disease Progression

The contribution of CD36 to AD pathology evolves throughout disease progression^{9Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer's disease pathology.2023 · Cell · DOI 10.1016/j.cell.2023.08.039 · PMID 37774677Open reference}:

Early Stage (Preclinical): CD36-mediated microglial activation may initially serve protective functions, promoting Aβ clearance and CNS homeostasis.

Intermediate Stage (Mild Cognitive Impairment): Persistent CD36 signaling leads to chronic neuroinflammation, creating a feed-forward loop that drives pathology progression.

Advanced Stage ( dementia ): Microglial dysfunction and CD36 dysregulation contribute to failure of Aβ clearance, accelerating cognitive decline.

Role in Parkinson’s Disease

Alpha-synuclein Recognition

While less characterized than in AD, CD36 has been implicated in Parkinson’s disease pathogenesis through its interaction with α-synuclein^{10Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.2023 · Journal of hepatology · DOI 10.1016/j.jhep.2022.09.025 · PMID 36243179Open reference}:

• α-Synuclein binding: CD36 can bind extracellular α-synuclein, triggering microglial activation

• Inflammatory responses: CD36-mediated signaling contributes to neuroinflammation in PD models

• Oxidative stress: The receptor’s involvement in oxidative lipid metabolism may exacerbate dopaminergic neuron loss

Evidence from PD Models

• CD36 expression is elevated in the substantia nigra of PD patients and animal models

• CD36 knockout mice show reduced microglial activation and improved dopaminergic neuron survival in MPTP models

• Lipid dysregulation mediated by CD36 may contribute to α-synuclein aggregation

Therapeutic Implications

CD36 as a Therapeutic Target

Given its central role in neuroinflammation, CD36 represents a promising therapeutic target for AD and related neurodegenerative diseases^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}0:

Small Molecule Inhibitors:

• CD36 antagonists can reduce Aβ-induced inflammatory signaling in vitro

• Several compounds have shown efficacy in mouse models of AD

• Challenges include blood-brain barrier penetration and selectivity

Biological Approaches:

• Monoclonal antibodies against CD36 extracellular domain block Aβ binding

• RNA interference approaches using siRNA or antisense oligonucleotides

• Gene therapy using viral vectors to modulate CD36 expression

Biomarker Potential

Soluble CD36 (sCD36) has been investigated as a potential biomarker for neurodegenerative diseases^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}1:

• Elevated sCD36 levels in cerebrospinal fluid (CSF) correlate with disease severity

• Diagnostic potential for early detection of AD

• Prognostic value for disease progression

CD36-Targeted Imaging

Novel imaging probes targeting CD36 are under development for:

• Amyloid plaque detection using CD36 as an alternative target

• Microglial activation imaging to monitor neuroinflammation in vivo

• Therapeutic monitoring of CD36-targeted interventions

Interaction with Other AD-Associated Proteins

CD36 and APOE

The Apolipoprotein E (APOE) gene represents the strongest genetic risk factor for late-onset AD. CD36 interacts with APOE in several ways^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}2:

• APOE-CD36 signaling: APOE4 enhances CD36-mediated inflammatory responses compared to APOE3

• Competition for binding: APOE and Aβ compete for CD36 binding, potentially modulating inflammatory outcomes

• Synergistic effects: Combined CD36 and APOE4 effects create a hyper-inflammatory phenotype

CD36 and TREM2

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is another critical microglial receptor implicated in AD:

• Complementary roles: While TREM2 mediates Aβ phagocytosis, CD36 primarily triggers inflammatory signaling

• Cooperative signaling: CD36 and TREM2 may cooperate in microglial responses to Aβ

• DAM formation: Both receptors contribute to disease-associated microglia (DAM) transformation

CD36 and TLRs

CD36 collaborates with Toll-like receptors (TLRs) in innate immune responses:

• TLR4-CD36 complex: CD36 and TLR4 form a receptor complex that synergistically enhances inflammatory responses to Aβ

• MyD88-dependent signaling: Both receptors utilize the MyD88 adaptor pathway

• Therapeutic targeting: Dual inhibition of CD36 and TLR4 may provide enhanced anti-inflammatory effects

Research Directions and Future Perspectives

Unresolved Questions

Several key questions remain regarding CD36 function in neurodegeneration:

1. Mechanistic understanding: How does CD36 signaling switch from protective to pathological in chronic disease?

2. Cell-type specificity: What determines microglial versus macrophage responses to CD36 engagement?

3. Temporal dynamics: How does CD36 function change across disease stages?

4. Therapeutic window: What is the optimal timing for CD36-targeted interventions?

Emerging Research Approaches

• Single-cell multiomics: Defining CD36+ microglial subpopulations in human AD brain

• Spatial transcriptomics: Mapping CD36 expression in relation to pathological landmarks

• Structural biology: Elucidating CD36-ligand interactions at atomic resolution

• Systems biology: Modeling CD36-centered gene networks in disease contexts

Structural Biology and Mechanism

Protein Structure

CD36 belongs to the class B scavenger receptor family, characterized by a distinctive structural organization:

Extracellular Domain:

• Large extracellular loop (~300 amino acids) containing ligand-binding sites

• Multiple disulfide bonds forming stable structural motifs

• N-linked glycosylation sites essential for proper folding and trafficking

• Conserved regions involved in oxidized LDL and Aβ binding

Transmembrane Regions:

• Two short transmembrane α-helices flanking the extracellular domain

• Anchor the protein in the plasma membrane

• Limit lateral mobility within the membrane plane

Intracellular Domains:

• Short N-terminal (6-10 aa) and C-terminal (10-14 aa) cytoplasmic tails

• Contain signaling motifs for Src family kinase interactions

• Phosphorylation sites regulate signaling capacity

• Palmitoylation contributes to membrane localization

Ligand Binding Mechanisms

CD36 demonstrates remarkable ligand versatility:

Amyloid-beta Binding^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}3:

• High-affinity binding to Aβ1-40 and Aβ1-42 oligomers

• Binding induces conformational changes in CD36

• Oligomer size influences binding affinity

• Competitively inhibited by certain Aβ antibodies

Oxidized LDL Recognition^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}4:

• Recognition of lipid peroxidation products (oxysterols, 4-hydroxynonenal)

• Apolipoprotein B-100 as structural component

• Scavenger receptor consensus sequence

• No downregulation despite continuous ligand exposure

Fatty Acid Transport:

• Long-chain fatty acid binding pocket (C16-C20)

• Allosteric regulation by fatty acid binding

• Concentration-dependent transport kinetics

• Tissue-specific expression patterns affect function

Signal Transduction Pathways

Immediate Signaling Events

CD36 engagement triggers rapid intracellular signaling cascades:

Src Family Kinase Activation^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}5:

• Lyn and Fyn kinases associate with CD36 cytoplasmic tail

• Rapid phosphorylation upon ligand binding

• Creates docking sites for downstream effectors

• Inibitors block CD36-mediated inflammatory responses

PI3K/Akt Pathway:

• PI3K recruitment to phosphorylated CD36

• Akt activation and downstream effects

• Links to metabolic regulation and survival

• mTOR pathway interaction

MAPK Cascades:

• ERK1/2 activation in response to CD36 ligands

• p38 MAPK involvement in stress responses

• JNK pathway activation in chronic stimulation

• Transcription factor activation (AP-1, NF-κB)

Downstream Transcription Factors

NF-κB Activation:

• Canonical pathway activation by CD36 signaling

• Pro-inflammatory cytokine transcription

• Sustained activation in chronic disease states

• Therapeutic target for anti-inflammatory strategies

AP-1 Activation:

• c-Fos/c-Jun heterodimer formation

• Gene expression programs for cell survival

• Matrix metalloproteinase regulation

• Implications for tissue remodeling

STAT Signaling:

• STAT1 activation in response to IFN-γ priming

• Amplification of inflammatory responses

• Cross-talk with other signaling pathways

CD36 in Model Systems

Mouse Models

CD36 Knockout Mice:

• Viable and fertile with mild phenotype

• Reduced Aβ-induced neuroinflammation

• Improved cognitive performance in AD models

• Altered lipid metabolism and adiposity

• Enhanced phagocytic capacity in some contexts

Transgenic Overexpression Models:

• Neuronal CD36 expression drives inflammation

• Microglial CD36 overexpression increases pathology

• Rescue experiments define cell-type specificity

• Tissue-specific promoters for targeted expression

Cellular Models

Primary Microglia Cultures:

• Aβ-induced CD36 upregulation

• Cytokine profiling in response to CD36 ligands

• Phagocytosis assays with CD36 modulation

• Migration and chemotaxis studies

iPSC-Derived Models:

• Human microglia-like cells from AD patients

• CD36 expression patterns in disease states

• Disease modeling and drug testing platforms

• Gene editing for mechanistic studies

Pharmacological Modulation

Small Molecule Inhibitors

Current Inhibitors:

• Sulfo-N-succinimidyl oleate (SSO): covalent inhibitor

• Blockade of fatty acid binding pocket

• Reduces inflammatory signaling in vitro

• Limited CNS penetration

Drug Development:

• Structure-based design of selective inhibitors

• Blood-brain barrier penetration optimization

• Safety and toxicity profiling

• Combination therapy approaches

Biological Therapeutics

Monoclonal Antibodies^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}6:

• Anti-CD36 antibodies block Aβ binding

• Reduce inflammatory cytokine production

• In vivo efficacy in mouse models

• Humanized antibodies in development

Antisense Oligonucleotides:

• siRNA-mediated CD36 knockdown

• ASO delivery to CNS

• Long-lasting effects with periodic dosing

• Clinical trial readiness

Gene Therapy Approaches

• AAV-mediated CD36 modulation

• CRISPR-based editing

• Cell-type specific expression control

• Regulated expression systems

Biomarker Development

Soluble CD36 as a Biomarker

Detection Methods^{2CD36 as a driver of microglial amyloid-beta phagocytosis in early Alzheimer's disease2023 · Cellular Immunology · PMID 36739842Open reference}7:

• ELISA for sCD36 quantification

• CSF and plasma measurements

• Correlation with disease severity

• Longitudinal monitoring potential

Clinical Utility:

• Early detection of cognitive decline

• Disease progression tracking

• Therapeutic response monitoring

• Complementary to existing biomarkers

Imaging CD36

PET Tracer Development:

• Radiolabeled CD36 ligands

• Microglial activation imaging

• Amyloid plaque detection alternative

• Human translation in progress

Cross-Species Comparisons

Evolutionary Conservation

• High conservation in mammals

• Functional orthologs in fish and amphibians

• Species-specific splice variants

• Disease model relevance

Therapeutic Translation

• Mouse to human extrapolation

• Cynomolgus monkey studies

• Safety assessment in non-human primates

• Clinical trial design considerations

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Microglia

• Neuroinflammation

• Amyloid-beta

• TREM2

• APOE

• Lipid Metabolism in Neurodegeneration

External Links

• NCBI Gene: CD36

• UniProt: CD36 (P16671)

• Ensembl: CD36

• OMIM: CD36 (173510)

• GeneCards: CD36